Abstract
Preclinical models suggest that refinoids inhibit mammary carcinogenesis. The induction of apoptosis is a unique feature of fenretinide, the most-studied retinoid in clinical trials of breast cancer chemoprevention, owing to its selective accumulation in breast tissue and its favorable toxicological profile. In a Phase III breast cancer prevention trial, fenretinide showed a strong trend of reduction of incidence of second breast malignancies in premenopausal women, which was confirmed by 15 years of follow-up. This warrants further research on the mechanisms of action and potential efficacy of fenrefinide and provides the rationale for a Phase III primary prevention trial in young women at high risk for breast cancer. This review will highlight the role of fenrefinide in breast cancer chemoprevention.
| Original language | English |
|---|---|
| Pages (from-to) | 423-432 |
| Number of pages | 10 |
| Journal | Expert Review of Anticancer Therapy |
| Volume | 7 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 2007 |
Fingerprint
Keywords
- Breast neoplasm
- Chemoprevention
- Clinical trial
- Fenretinide
- Retinoid
ASJC Scopus subject areas
- Cancer Research
- Pharmacology
Cite this
Synthetic retinoid fenretinide in breast cancer chemoprevention. / Bonanni, Bernardo; Lazzeroni, Matteo; Veronesi, Umberto.
In: Expert Review of Anticancer Therapy, Vol. 7, No. 4, 04.2007, p. 423-432.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Synthetic retinoid fenretinide in breast cancer chemoprevention
AU - Bonanni, Bernardo
AU - Lazzeroni, Matteo
AU - Veronesi, Umberto
PY - 2007/4
Y1 - 2007/4
N2 - Preclinical models suggest that refinoids inhibit mammary carcinogenesis. The induction of apoptosis is a unique feature of fenretinide, the most-studied retinoid in clinical trials of breast cancer chemoprevention, owing to its selective accumulation in breast tissue and its favorable toxicological profile. In a Phase III breast cancer prevention trial, fenretinide showed a strong trend of reduction of incidence of second breast malignancies in premenopausal women, which was confirmed by 15 years of follow-up. This warrants further research on the mechanisms of action and potential efficacy of fenrefinide and provides the rationale for a Phase III primary prevention trial in young women at high risk for breast cancer. This review will highlight the role of fenrefinide in breast cancer chemoprevention.
AB - Preclinical models suggest that refinoids inhibit mammary carcinogenesis. The induction of apoptosis is a unique feature of fenretinide, the most-studied retinoid in clinical trials of breast cancer chemoprevention, owing to its selective accumulation in breast tissue and its favorable toxicological profile. In a Phase III breast cancer prevention trial, fenretinide showed a strong trend of reduction of incidence of second breast malignancies in premenopausal women, which was confirmed by 15 years of follow-up. This warrants further research on the mechanisms of action and potential efficacy of fenrefinide and provides the rationale for a Phase III primary prevention trial in young women at high risk for breast cancer. This review will highlight the role of fenrefinide in breast cancer chemoprevention.
KW - Breast neoplasm
KW - Chemoprevention
KW - Clinical trial
KW - Fenretinide
KW - Retinoid
UR - http://www.scopus.com/inward/record.url?scp=34247559202&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247559202&partnerID=8YFLogxK
U2 - 10.1586/14737140.7.4.423
DO - 10.1586/14737140.7.4.423
M3 - Article
C2 - 17428163
AN - SCOPUS:34247559202
VL - 7
SP - 423
EP - 432
JO - Expert Review of Molecular Diagnostics
JF - Expert Review of Molecular Diagnostics
SN - 1473-7159
IS - 4
ER -